©2022 Stanford Medicine
Safety Testing of Adding Nivolumab to Chemotherapy in Patients With Intermediate and High-Risk Local-Regionally Advanced Head and Neck Cancer
Trial ID: NCT02764593
This study will evaluate the safety of adding nivolumab to several chemotherapy platforms with weekly cisplatin, high-dose cisplatin, cetuximab or radiation therapy alone.
Safety Evaluations of Nivolumab (Anti-PD-1) Added To Chemotherapy (CRT) Platforms In Patients With Intermediate And High-Risk Local-Regionally Advanced Head and Neck Squamous Cell Carcinoma
A. Dimitrios Colevas, MD
Professor of Medicine (Oncology) and, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS) and of Radiation Oncology (Radiation Therapy)
Quynh-Thu Le, MD
Katharine Dexter McCormick and Stanley McCormick Memorial Professor and Professor, by courtesy, of Otolaryngology - Head & Neck Surgery (OHNS)
- Histologically or cytologically-confirmed diagnosis of HNSCC of the oral cavity,
oropharynx, larynx, or hypopharynx.
- Intermediate-risk group: Oropharynx cancer that is p16-positive by
immunohistochemistry with smoking status > 10 Pack-years, stage T1-2N2b-N3 OR ≤ 10
pack-years, stage T4N0-N3 or T1-3N3.
- High-risk group: Oral cavity, larynx, hypopharynx, or p16-negative oropharynx cancer,
stage T1-2N2a-N3 or T3-4-N0-3 based on the following diagnostic workup:
- Mandatory submission of H&E and p16 stained slides for central review of p16
staining is required for oropharyngeal patients and H&E stained slide block (or
punch biopsy of paraffin block) for PD-L1 expression analysis for all patients
- History/physical examination within 28 days prior to registration
- Examination by Radiation Oncologist, Medical Oncologist, and Ear, Nose, Throat
(ENT) or Head & Neck Surgeon within 28 days prior to registration
- Fiberoptic exam with laryngopharyngoscopy within 28 days prior to registration
- Diagnostic quality, cross sectional imaging of the thorax within 28 days prior to
registration; 18-F-FDG-PET/CT or conventional CT are acceptable.
- Diagnostic quality CT or MRI of neck, with contrast, within 28 days prior to
registration; a 18-F-FDG-PET/CT of the neck only is acceptable as a substitute if
the CT is of diagnostic quality and with IV contrast.
- Age ≥ 18 years
- The trial is open to both genders
- Definitive clinical or radiologic evidence of distant (beyond cervical lymph node and
neck tissue) metastatic disease.
- Patients with oral cavity cancer are excluded from participation if resection of the
primary tumor is considered technically feasible by an oral or head and neck cancers
- Carcinoma of the neck of unknown primary site origin (even if p16-positive).
- Absence of RECIST, v. 1.1 defined measurable disease.
- Gross total excision of both primary and nodal disease; this includes tonsillectomy,
local excision of primary site, and nodal excision that removes all clinically and
radiographically evident disease. Patients with RECIST, v. 1.1 evaluable remaining
cancer either in the neck or primary site remain eligible.
- Simultaneous primary cancers or separate bilateral primary tumor sites.
- Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
for a minimum of 3 years; (for example, carcinoma in situ of the breast, oral cavity,
or cervix are all permissible).
- Prior systemic chemotherapy for the study cancer.
- Prior radiotherapy to the region of the study cancer that would result in overlap of
radiation therapy fields.
- Patients with active autoimmune disease, with exceptions of vitiligo, type I diabetes
mellitus, hypothyroidism and psoriasis.
- Use of systemic corticosteroids (> 10 mg daily prednisone or equivalent) or other
immunosuppressive medications within 14 days of study drug administration, with
exception of inhaled or topical steroids.
- Known immunosuppressive disease, for example HIV infection or history of bone marrow
transplant or chronic lymphocytic leukemia (CLL).
School of Medicine
300 Pasteur Drive
Stanford, CA 94305